Kriyā

Kriya Announces Three Presentations at the 2024 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting

Retrieved on: 
Jeudi, mai 2, 2024
FDA, Efficacy, Inflammation, DSM-IV codes, C5, Research, Abstract, Geographic atrophy, Paratriathlon, Primate, Sodium iodate, Immunoassay, AAV, Retina, ONL, Patient, Neurology, PALO, Kriyā, Mouse, Annual general meeting, Therapy, ARVO, Vaccine

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced three presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will be held May 5 to 9, 2024 in Seattle, WA.

Key Points: 
  • PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., May 02, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced three presentations at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, which will be held May 5 to 9, 2024 in Seattle, WA.
  • Kriya’s pipeline includes gene therapies across several therapeutic areas including ophthalmology, metabolic disease and neurology.
  • Broad coverage was achieved from the injection site to the posterior pole, including the macula and retina.
  • The study demonstrates, in a dose dependent manner, the potential of AAV.CR2-CR1 to preserve the photoreceptor-containing outer nuclear layer (ONL).

Kriya Announces Six Presentations at the American Society of Gene & Cell Therapy (ASGCT) Annual Meeting 2024

Retrieved on: 
Lundi, avril 22, 2024
Common, EDT, DSM-IV codes, Computational biology, Cell, AAV, Therapy, Gene, Neurology, Society, AlphaFold, PALO, Kriyā, GMP, Ophthalmology, Vaccine

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., April 22, 2024 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced six presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting, which will be held May 7 to 11, 2024 in Baltimore, MD.

Key Points: 
  • Kriya has established a fully integrated gene therapy product development engine including cutting-edge research, computational biology and scalable in-house GMP manufacturing deploying next-generation upstream and downstream processes and analytical characterization techniques.
  • The presentations describe core technologies and manufacturing platform capabilities that support the Company's pipeline of gene therapies in ophthalmology, metabolic disease and neurology.
  • Kriya is also sponsoring a symposium entitled “Advancing Gene Therapy for Common Diseases: from Concept to Reality”.
  • (Abstract 957)
    Title: Prequalification of analytical test methods for determining the potency of an adeno-associated virus-based gene therapy product, A. Bries et al.

Kriya to Present at the J.P. Morgan 42nd Annual Healthcare Conference

Retrieved on: 
Mercredi, décembre 20, 2023
Kriyā, Entrepreneurship, Conference, PALO, Therapy

PALO ALTO, Calif., and RESEARCH TRIANGLE PARK, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced that Shankar Ramaswamy, M.D., Co-Founder and CEO, will present at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9th, at 9:00 AM PT in San Francisco, California.

Key Points: 
  • PALO ALTO, Calif., and RESEARCH TRIANGLE PARK, N.C., Dec. 20, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies to address common diseases affecting millions of people around the world, today announced that Shankar Ramaswamy, M.D., Co-Founder and CEO, will present at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9th, at 9:00 AM PT in San Francisco, California.

Everads Enters License Agreement with Kriya for Development of Ocular Gene Therapy Candidates Using Everads' Suprachoroidal Delivery Technology

Retrieved on: 
Mercredi, septembre 27, 2023
Sclera, Eye, TEL, Choroid, Translational Vision Science & Technology, Kriyā, Retina, Pharmaceutical industry, Medical device

The agreement follows a research collaboration between the parties whereby Everads' platform was evaluated for delivery of the company's gene therapy candidates in non-human primate models.

Key Points: 
  • The agreement follows a research collaboration between the parties whereby Everads' platform was evaluated for delivery of the company's gene therapy candidates in non-human primate models.
  • Under the terms of the agreement, Kriya was granted field-based exclusivity for use of Everads' platform using gene therapy against certain prespecified therapeutic targets including ophthalmic diseases that involve the complement cascade, while Everads retains the right to continue using and/or licensing its technology to other parties for the development of other therapeutic targets using gene therapy, as well as all non-gene therapy applications.
  • Everads received an undisclosed upfront payment and is entitled to receive development milestones and royalties on net sales of products using Everads' platform.
  • "We are extremely excited to enter into this license agreement after a thorough evaluation of our technology and its applicability for delivery of gene therapy.

Kriya Announces Exclusive License and Collaboration Agreement with Everads to Advance Gene Therapies for Prevalent Diseases in Ophthalmology Including Geographic Atrophy

Retrieved on: 
Mercredi, septembre 27, 2023
Drug delivery, Retina, Injection, CR2, Pediatrics, IgG4-related ophthalmic disease, Sclera, Eye, Geographic atrophy, Quality of life, Intravitreal injection, Inflammation, AAV, Complement, RESEARCH, Administration, C3, Choroid, Stanford University School of Medicine, Patient, CR1, PARK, Entrepreneurship, FDA, Therapy, Emotional dysregulation, Disease, Pharmaceutical industry, Medical device, Vaccine, Ophthalmology, Kriyā, C5

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 27, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc. ("Kriya"), a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world, has entered into an exclusive license, collaboration and supply agreement with Everads Therapy, Ltd (“Everads”) to advance Kriya’s portfolio of gene therapies for retinal diseases using Everads' suprachoroidal delivery device. Everads is a private biotech company that has developed a novel technology enabling targeted delivery of therapies to the retina via the suprachoroidal space, an anatomical compartment located between the sclera and choroid that traverses the circumference of the posterior segment of the eye. Suprachoroidal delivery is an emerging, non-surgical route of administration in ophthalmology. Specifically in delivery of gene therapy, this route of administration offers the potential to enhance the efficiency of gene therapy delivery to the retina while minimizing intraocular inflammation.

Key Points: 
  • Specifically in delivery of gene therapy, this route of administration offers the potential to enhance the efficiency of gene therapy delivery to the retina while minimizing intraocular inflammation.
  • The transaction enables Kriya’s access to Everads’ suprachoroidal delivery technology to deliver multiple prespecified gene therapy product candidates for several ophthalmic diseases, including those involving the complement cascade.
  • “I am quite optimistic and convinced that innovative therapies will continue to improve the lives of people with geographic atrophy and other serious ophthalmic diseases.
  • A gene therapy targeting the C3 and C5 pathways delivered by a suprachoroidal injection may be a significant improvement in the treatment of geographic atrophy.”

Kriya Acquires Tramontane Therapeutics and Launches Gene Therapy Program for Nonalcoholic Steatohepatitis (NASH) and Other Prevalent Diseases

Retrieved on: 
Mercredi, septembre 6, 2023
Obesity, NASH, Half-life, PALO, Type 1 diabetes, Research, FGF21, AAV, UAB, RESEARCH, Fibrosis, Molecular biology, Instituto Universitario de Restauración del Patrimonio of the Universitat Politècnica de València, Fibroblast growth factor, PARK, Liver, Tramontane, Entrepreneurship, DSM-IV codes, Therapy, Disease, Safety, Conditional sentence, Pharmaceutical industry, Vaccine, Biochemistry, Kriyā

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc., ("Kriya") a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world, today announced that it has acquired Tramontane Therapeutics, Inc. ("Tramontane"). Tramontane is a private gene therapy company focused on developing treatments for metabolic and neurodegenerative diseases. Tramontane, a spin out from Universitat Autònoma de Barcelona (UAB), is now a wholly owned subsidiary of Kriya.

Key Points: 
  • Tramontane is a private gene therapy company focused on developing treatments for metabolic and neurodegenerative diseases.
  • Tramontane, a spin out from Universitat Autònoma de Barcelona (UAB), is now a wholly owned subsidiary of Kriya.
  • "The addition of Tramontane’s FGF21 program strategically aligns with our Metabolic Disease portfolio which also includes a one-time gene therapy candidate for insulin-dependent diabetes."
  • I believe that a one-time gene therapy would be a quantum leap forward in the management of this chronic disease."

Rob Scholl Named President & CEO of Textron Specialized Vehicles Inc.; Kriya Shortt Named President & CEO of Textron eAviation

Retrieved on: 
Lundi, août 21, 2023
Insurance, Finance, Other Energy, Chemicals, Plastics, Automotive Manufacturing, Aerospace, Professional Services, Manufacturing, Energy, McCauley Propeller Systems, Business development, Inc., Part program, Marketing, Part, TSV, Acosta Sales & Marketing, Aviation, Business, Multimedia, United Nations Convention on Contracts for the International Sale of Goods, Textron Aviation, Scholl, Customer service, Corporation, Donnelly (surname), Flight operations quality assurance, NYSE, Management, Textron, Kriyā

Textron Inc. (NYSE: TXT) today announced that Rob Scholl, president & CEO of Textron eAviation, has been named president & CEO of Textron Specialized Vehicles Inc. and Kriya Shortt, senior vice president, Global Parts & Distribution, at Textron Aviation, has been named president & CEO of Textron eAviation, succeeding Scholl.

Key Points: 
  • Textron Inc. (NYSE: TXT) today announced that Rob Scholl, president & CEO of Textron eAviation, has been named president & CEO of Textron Specialized Vehicles Inc. and Kriya Shortt, senior vice president, Global Parts & Distribution, at Textron Aviation, has been named president & CEO of Textron eAviation, succeeding Scholl.
  • With 17 years of experience at Textron, Scholl has served in leadership roles across the company, including senior vice president, Global Sales & Flight Operations, vice president, Parts & Programs and vice president, Marketing at Textron Aviation.
  • Most recently, she served as senior vice president, Global Parts & Distribution, and president of Able Aerospace and McCauley Propeller Systems.
  • She has also served as senior vice president, Customer Service, senior vice president, Sales, and vice president, International Sales.

Kriya Announces $150 Million Addition to its Series C, Bringing Total Round to over $430 Million to Further its Mission of Delivering Gene Therapies for Prevalent Diseases

Retrieved on: 
Mercredi, juillet 26, 2023
DSM-IV codes, PALO, Research, RESEARCH, Investment, Patient, Ophthalmology, Engineering, Series, Entrepreneurship, Rare, Therapy, Neurology, PARK, Pharmaceutical industry, Kriyā

PALO ALTO, Calif. and RESEARCH TRIANGLE PARK, N.C., July 26, 2023 (GLOBE NEWSWIRE) -- Kriya Therapeutics, Inc., a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world, today announced the addition of over $150 million in capital committed as part of its Series C Financing, bringing the total Series C round to over $430 million. Proceeds from the financing will support the clinical translation of Kriya’s broad pipeline of gene therapies and continued scaling of its engineering, computational and manufacturing platforms. Since its founding in October 2019, Kriya has raised over $600 million in committed capital —and with this financing, Kriya’s cash runway is anticipated to run into late 2026.

Key Points: 
  • Proceeds from the financing will support the clinical translation of Kriya’s broad pipeline of gene therapies and continued scaling of its engineering, computational and manufacturing platforms.
  • Since its founding in October 2019, Kriya has raised over $600 million in committed capital —and with this financing, Kriya’s cash runway is anticipated to run into late 2026.
  • Kriya is developing a portfolio of transformational gene therapies focused on three main therapeutic areas: ophthalmology, neurology and metabolic disease.
  • “We have an ambitious goal to advance gene therapies to highly prevalent diseases that affect millions of people around the world,” said Shankar Ramaswamy, M.D., Co-Founder and CEO of Kriya.

DeepBook Launches as the First Native Liquidity Layer for Building on Sui

Retrieved on: 
Mercredi, juillet 12, 2023
Technology, Finance, Security, Fintech, Professional Services, Software, Digital Cash Management, Digital Assets, Blockchain, Networks, Cryptocurrency, Mechanics, Decentralized finance, CLOB, Cetus, Trust, UX, Architecture, Ecosystem, DEX, Environment, Online shopping, Mark (given name), Kriyā

Sui community members including MovEX and Mysten Labs helped with the technical aspects of DeepBook required for integration into the network.

Key Points: 
  • Sui community members including MovEX and Mysten Labs helped with the technical aspects of DeepBook required for integration into the network.
  • DeepBook, in turn, leverages Sui’s industry-leading performance to deliver a low latency and high execution engine to supply robust liquidity to the entire Sui DeFi ecosystem.
  • Structured as a central limit order book, DeepBook also extends the flexible, composable liquidity of community-built AMMs, providing the best of both worlds for the Sui ecosystem.
  • “We support the creation of DeepBook as a public good for the Sui ecosystem to advance the network and support all of the developers building on Sui,” said Siourounis.

Kriya to Present 10 Abstracts at the 2023 American Society of Gene and Cell Therapy Annual Meeting

Retrieved on: 
Mardi, mai 2, 2023
Health, Neurology, Genetics, Clinical Trials, Pharmaceutical, Biotechnology, Abstract, Gene, PT, DSM-IV codes, Ophthalmology, Cell, Entrepreneurship, Therapy, Society, Communications satellite, Kriyā

Kriya Therapeutics, Inc. , a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world, today announced that it will present 10 abstracts at the 26th Annual Meeting of the American Society of Gene and Cell Therapy ( ASGCT ) taking place in Los Angeles, CA, May 16-20, 2023.

Key Points: 
  • Kriya Therapeutics, Inc. , a biopharmaceutical company developing gene therapies for conditions affecting millions of people around the world, today announced that it will present 10 abstracts at the 26th Annual Meeting of the American Society of Gene and Cell Therapy ( ASGCT ) taking place in Los Angeles, CA, May 16-20, 2023.
  • Kriya’s abstracts include two oral presentations and eight posters on its core technology and manufacturing platforms as well as its diverse pipeline of gene therapies for ophthalmology, neurology, and metabolic diseases.
  • “We are excited to share updates as we continue to advance our diverse pipeline of gene therapies,” said Shankar Ramaswamy, M.D., Co-Founder and CEO of Kriya.
  • “Our team has made significant progress in areas critical to the development, manufacturing, and characterization of gene therapies, and we look forward to presenting at this year's ASGCT."